NCT02944396 - Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 23, 2016

Primary Completion Date

October 2, 2019

Study Completion Date

October 2, 2019

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

pemetrexed

intravenous; administered on Day 1 via infusion in a 21-day cycle

DRUG

nivolumab

intravenous; administered on Day 1 via infusion in a 21-day cycle

DRUG

paclitaxel

intravenous; administered on Day 1 via infusion in a 21-day cycle

DRUG

veliparib

oral capsule; varying doses administered on Days -2 to 5 in a 21-day cycle

DRUG

carboplatin

intravenous; administered on Day 1 via infusion in a 21-day cycle

Trial Locations (6)

University of Alabama at Birmingham - Main /ID# 155135, Birmingham

Goshen Center for Cancer Care /ID# 153822, Goshen

Univ of Colorado Cancer Center /ID# 153820, Aurora

Icri /Id# 155593, Whittier

University of Chicago /ID# 153824, Chicago

Duke University Medical Center /ID# 153821, Durham